Background. The incidence of thyroid cancer is increasing worldwide. The findings of up to 30% of thyroid fine-needle aspiration biopsies (FNAB) are inconclusive, primarily as a result of several thyroid histologic subtypes with overlapping cytologic features. MicroRNAs (miRNAs) are small noncoding RNAs and have been implicated in carcinogenesis. We hypothesized that there are miRNAs that are differentially expressed between benign and malignant thyroid tumors that are difficult to distinguish by FNAB. Methods. The expression of 1263 human miRNAs was profiled in 47 tumor samples representing difficult to diagnose histologic subtypes of thyroid neoplasm (21 benign, 26 malignant). Differentially expressed miRNAs were validated by quantitative real-time reverse transcriptase-polymerase chain reaction. The area under the receiver operating characteristic curve (AUC) was used to determine the diagnostic accuracy of differentially expressed miRNAs. Results. Supervised hierarchical cluster analysis demonstrated grouping of 2 histologies (papillary and follicular thyroid carcinoma). A total of 34 miRNAs were differentially expressed in malignant compared to benign thyroid neoplasms (P \ 0.05). A total of 25 of the 34 nonproprietary miRNAs were selected for validation, and 15 of the 25 miRNAs were differentially expressed between benign and malignant samples with P-value \ 0.05. Seven miRNAs had AUC values of[0.7. miR-7 and miR-126 had the highest diagnostic accuracy with AUCs values of 0.81 and 0.77, respectively. Conclusion. To our knowledge, this is the first study to evaluate the diagnostic accuracy of miRNAs in thyroid histologies that are difficult to distinguish as benign or malignant by FNAB. miR-126 and miR-7 had high diagnostic accuracy and could be helpful adjuncts to thyroid FNAB.
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Thyroid cancer is the most common endocrine malignancy. It arises from 2 cell types (follicular and parafollicular cells) with follicular cell-derived thyroid cancer accounting for approximately 95% of all thyroid cancers cases. [1] [2] [3] Thyroid cancer incidence has doubled in the last 3 decades and it is estimated that there will be more than 44,000 new cases and 1690 deaths in 2011 in the United States. [4] [5] [6] Fine-needle aspiration biopsy (FNAB) and cytologic examination is the gold-standard in the work up of a thyroid nodule to exclude a cancer diagnosis. [7] [8] [9] [10] [11] The cytologic finding of a fine-needle aspiration can be grouped into 6 categories (nondiagnostic or unsatisfactory sample, benign, follicular lesion of undetermined significance, follicular neoplasm or suspicious for a follicular neoplasm, suspicious for malignancy, and malignant) based on the Bethesda System for Reporting Thyroid Cytopathology with each category associated with a different malignancy risk (benign 0-3%; follicular lesion of undetermined significance 5-15%; follicular neoplasm or suspicious for a follicular neoplasm 15-30%; suspicious for malignancy 60-75%; and malignant 97-99%). 12 Although FNAB has relatively high sensitivity and specificity (65-98% and 72-100%, respectively) for those lesions that are definitively categorized as benign or malignant, up to 10-25% of the lesions are interpreted as indeterminate without a definitive cytological diagnosis. 8, [13] [14] [15] [16] Follicular and Hürthle cell neoplasms pose a challenge as the cytological features between adenomas and carcinomas are indistinguishable. 17, 18 Thyroidectomy is commonly recommended for lesions interpreted as indeterminate or suspicious as a result of the high risk of malignancy and the extent of surgery may vary depending on the final histology, tumor size of the lesion, and the patients' risk factors for malignancy and patient preference. 8, [10] [11] [12] At a minimum, thyroid lobectomy is recommended for lesions interpreted as follicular neoplasm or suspicious for a follicular neoplasm in order to reach a definitive histological diagnosis. However, given a malignancy risk of 15-30% for these indeterminate lesions, the vast majority of final pathologic diagnoses are benign rendering many of the surgical interventions unnecessary.
Our understanding of the molecular basis of thyroid neoplasm has improved and numerous investigators have evaluated molecular markers to improve the accuracy of thyroid cancer diagnosis given the limitations of thyroid FNAB mentioned above. 3, 13, [19] [20] [21] [22] [23] Among these efforts include investigations on clinical and tumor characteristics to create a diagnostic predictor model, combined analysis of clinical factors and candidate diagnostic markers, and the detection of common somatic mutations and gene rearrangements associated with thyroid cancer. [24] [25] [26] [27] [28] [29] [30] [31] Recently there has been increasing interest in examining the expression profile of microRNAs (miRNAs) in thyroid cancers to not only understand tumorigenesis, but also to improve thyroid cancer diagnosis. [32] [33] [34] [35] [36] These studies have, however, focused on identifying differentially expressed miRNA in papillary thyroid cancer and not the histologic subtypes that are challenging to diagnose on FNAB.
miRNAs are small noncoding RNAs of approximately 21-23 nucleotides long and they function as regulatory molecules by binding to target messenger RNA (mRNA) in the 3 0 -untranslated region, leading to either repression of mRNA translation or promoting degradation. 37 32 Although there have been several investigations which have identified miRNAs that are dysregulated among different histologic types of thyroid neoplasms, there has not been a study that addresses the specific histologies that are difficult to diagnose on FNAB as a whole. Thus, the goals of our study were to perform microRNA profiling on thyroid tissue samples by means of microarray analysis to identify miRNAs that are dysregulated between benign and malignant histologies that are difficult to diagnose by FNAB and to validate the result of tissue microarray by quantitative realtime polymerase chain reaction (qRT-PCR). [FC] ) on the basis of secondary review of the procured tissue sample by an endocrine pathologist. MNG samples were initially interpreted as indeterminate (follicular neoplasm) on preoperative FNAB, and permanent histologic examination demonstrated hyperplastic nodule in the setting of MNG. Normal thyroid tissue was obtained from patient undergoing thyroidectomy for benign or malignant disease from the contralateral thyroid lobe. All the thyroid tissue samples, except normal, included in the analysis were interpreted as either indeterminate (follicular neoplasm/lesion) or suspicious for malignancy on the preoperative thyroid FNAB.
MATERIALS AND METHODS

Tissue Samples
RNA Isolation
RNA extraction was performed with TriZol (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. RNA quantity and quality were determined with NanoDrop (Thermo Scientific, Wilmington, DE) and the Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA).
miRNA Microarray Profiling and Data Analysis
Total RNA (200 ng) from 47 tissue samples (21 benign and 26 malignant) was submitted for microarray profiling. Pooled RNA of all 68 samples that were submitted was used as the reference RNA. Total RNA from each sample and reference RNA was labeled with Hy3 and Hy5 fluorescent labels, respectively, using the miRCURY LNA Array power labeling kit (Exiqon) as described by the manufacturer. Fluorescent labeled RNA samples were mixed pair wise and hybridized to the miRCURY LNA array version 11.0 (Exiqon) containing 1263 probes from miRBase version 14.0. Arrays were scanned with the Agilent 62505M Microarray scanner, and the spot intensities were measured by ImaGene image analysis software (BioDiscovery, El Segundo, CA). Data were normalized by R scripts (Bioconductor). For each miRNA probe, log2 ratio of Hy3 and Hy5 signals were calculated. A 2-tailed t-test was used to compare expression levels between benign and malignant histologies.
qRT-PCR
Statistically significant differentially expressed miRNAs based on miRNA microarray were validated by qRT-PCR that used total RNA from the same 47 tissue samples analyzed on microarray. qRT-PCR was carried out using TaqMan microRNA assay probes (Applied Biosystems, Foster City, CA ) and the control with the lowest variability among all the tissue samples (miR-625*) was selected for the endogenous control. miRNA expression level was calculated using delta cycle threshold (DCt), which is the cycle threshold (Ct) of the miRNA of interest subtracted by the Ct value of the endogenous control (miR-625*). Fold difference between benign and malignant samples was determined by the formula (Fold change = 2 -DDCt ), and DDCt was calculated by normalizing the DCt to the endogenous control sample, in this case RNA from the TPC-1 cell line.
Statistical Analysis
The Mann-Whitney U-test was used to compare miRNA expression levels by histologic diagnosis. A P-value of less than 0.05 was considered worthy of further evaluation. A Pearson correlation coefficient (r) was calculated on microarray and qRT-PCR data to assess the amount of correlation between the 2 assays. The area under the receiver operating characteristic curve (AUC) was calculated on the 15 most significant miRNAs, and receiver operating curve was plotted for the top 2 statistically significant miRNAs.
RESULTS
Tissue Sample Microarray
miRNA microarray was performed on a total of 47 tissue samples, 21 benign (6 FA, 8 MNG, 7 HCA) and 26 malignant (8 HCC, 6 PTC, 6 FPTC, 6 FC). Thirty-four miRNAs were found to be differentially expressed between benign and malignant samples with P-value \0.05 (Fig. 1a) . miR-146b-5p and miR-222 were upregulated more than 2-fold and miR-451, miR-7, and miR-144 were downregulated more than 2-fold compared to the benign samples (Table 1) . Interestingly, miR-221 and miR-222, which have been demonstrated consistently to be upregulated in thyroid malignancy in previous studies, were also found to be upregulated in our study. [32] [33] [34] [46] [47] [48] Supervised hierarchical clustering of the 34 most differentially expressed miRNAs demonstrated clustering of papillary thyroid cancer and follicular thyroid cancer but overall there was no clear separation between benign and malignant samples (Fig. 2) .
Validation of Differentially Expressed miRNAs by Real-time qRT-PCR
A total of 25 miRNAs were nonproprietary and were selected for validation among the 34 differentially expressed miRNAs. There was similar up-and downregulation profile between microarray and TaqMan ( Fig. 1 ) in up to 79% of the miRNAs. The average fold difference values by qRT-PCR TaqMan for each miRNA were plotted against the fold change values obtained from microarray data and the Pearson correlation coefficient (r) was 0.69 with R 2 of 0.48 (Fig. 3) . Fifteen out of 25 miRNAs were found to be significantly differentially expressed (P \ 0.05) between benign and malignant samples ( Table 2) . miR-32* did not amplify on TaqMan PCR. The AUC was calculated for the 15 most significant miRNAs, and 9 miRNAs had AUC values greater than 0.70 (Table 3) . miR-126 and miR-7 had the highest AUC values indicating that these miRNAs had the greatest potential as diagnostic markers (Fig. 4) .
Subgroup Analysis of Candidate miRNAs
Subgroup analyses of the 2 candidate microRNAs (miR-126 and miR-7) were performed on the miRNA validated by qRT-PCR. Three different comparisons were performed by the Mann-Whitney U-test: (1) FA versus FC; (2) HCA versus HCC; and (3) FA/HCA versus FC/HCC/ FPTC. Both miRNAs were significantly differentially expressed within the first group (P = 0.01 and P = 0.03, miR-126 and miR-7, respectively) and miR-126 was significantly differentially expressed within the third group (P = 0.03). The other comparisons did not reach statistical significance (P = 0.64 and P = 0.56, miR-126 and miR-7, respectively in group 2; miR-7 in group 3 had P-value of 0.13). The same subgroup analyses were performed on the other miRNAs that were validated on the tissue samples and miR-144, -145, and -195 were significantly differentially expressed in group 1 comparison (P = 0.02, P = 0.01, P = 0.01, respectively) and the remainder of miRNAs did not reach statistical significance. 
DISCUSSION
In this study, we identified differentially expressed miRNAs in difficult to diagnose thyroid histologic subtypes in an effort to identify diagnostically useful markers. We found 34 differentially expressed miRNAs by miRNA microarray analysis in a diverse group of benign versus malignant thyroid histologies. A total of 25 of those 34 miRNAs were validated by TaqMan qRT-PCR, and there was good correlation between microarray data and TaqMan data. Fifteen out of the 25 miRNAs were confirmed to be differentially expressed by qRT-PCR and 9 out of those 15 miRNAs were found to have AUC values [0.7 in the distinction of benign versus malignant lesions. Subgroup analysis indicated that both miR-126 and miR-7 were statistically significantly differentially expressed between FA and FC, and miR-126 was significantly differentially expressed in FC, HCC, and FPTC as compared to FA and HCA.
As the incidence of thyroid cancer is increasing, there is a pressing need to improve the accuracy of thyroid cancer diagnosis, in particular for those histologic subtypes with features difficult to diagnose by FNAB. Although the routine use of FNAB significantly reduced the number of unnecessary thyroid surgeries while increasing the yield of malignancy in the thyroidectomy specimen, it has limitations as up to 30% of FNAB results are inconclusive requiring diagnostic thyroidectomies. [13] [14] [15] [16] [50] [51] [52] For these biopsies requiring surgical intervention for definitive histological diagnosis, the vast majority will turn out having benign disease. 51, 53 Several investigators have identified dysregulated miRNAs in thyroid cancer with implications on diagnostic utility. Pallante et al. performed genome-wide miRNA expression profiling comparing normal thyroid tissue and papillary thyroid cancer and found marked upregulation of miR-221, -222, and -181b. 34 They were able to validate this result in FNAB specimens by demonstrating the same trend of upregulation in specimen that were found to be malignant on postoperative histology. Nikiforova et al. performed microRNA profiling on a smaller scale using TaqMan microRNA Assays Human Panel designed to detect 158 human microRNAs and analyzed miRNA expression levels in thyroid tumors and normal thyroid tissue. 33 In this study, they were able to demonstrate distinct miRNA expression profiles among different histopathological subtypes, and they concluded that a set of 7 miRNAs (miR-187, -221, -222, -146b, -155, -224, and -197) were highly accurate in distinguishing thyroid cancers from hyperplastic nodules. Furthermore, they tested these miRNAs on 62 consecutive FNAB samples and these miRNAs were upregulated in all 8 specimens (7 PTC and 1 FTC oncocytic type) that ultimately turned out to be malignant. A caveat to this study is that only 13 out of 62 patients had surgery (4 FNAB interpreted as malignant and 8 with atypical cytology) with complete histological information. Of the remaining 49 samples, 3 of them had upregulation of 1 to 3 of these miRNAs but because these patients did not undergo surgery it is difficult to interpret the data without complete histologic information. Chen et al. studied 7 miRNAs (miR-146a, -146b, -155, -187, -221, -222) based on previous literature and were able to confirm upregulation of miR-146b, -221, and -222 in PTC compared to FA. 32 They tested additional histologic subtypes and concluded that miR-146b best distinguishes PTC from other nonpapillary carcinoma groups. Furthermore, they tested these miRNAs on FNAB specimen and confirmed upregulation of miR-146b in papillary thyroid cancer compared to FA and hyperplastic nodules.
Interestingly, miR-221 and miR-222 were only statistically significantly upregulated in the comparison of PTC versus FA but not between PTC versus hyperplastic nodule. There was no statistically significant difference found in these miRNAs among the classical PTC versus the follicular variants. While all of these studies demonstrate differential expression of miRNAs among diverse groups of thyroid histologies, none have specifically evaluated if a set of miRNAs in the difficult to diagnose histologic subtypes of thyroid neoplasm have diagnostic utility as an adjunct to thyroid FNAB. This is important because thyroid FNAB result that are indeterminate/suspicious on cytologic examination are mostly made up of histologic subtypes of thyroid tissue samples we studied (hyperplastic nodule, FA, HCA, HCC, FC, FPTC, PTC).
MiRNA profiling performed in our study confirmed the upregulation of 3 miRNAs (miR-146b, -221, and miR-222) observed in other studies to be upregulated in PTC; however, their expression was not statistically significant on TaqMan qRT-PCR validation in the difficult to diagnose histologic groups. Chou et al. demonstrated that upregulation of these 3 miRNAs has significant association with extrathyroidal invasion and demonstrated miR-146b level to be much higher in PTC with BRAF mutation than tumors without the mutation. 54 They also demonstrated as a putative target of miR-221 and miR-222, indicating potential therapeutic targets for these miRNAs. 36 The miRNAs that were statistically significantly differentially expressed in our study were miR-7 and miR-126; both were found to be downregulated in malignant thyroid tumors compared to benign tumors. These miRNAs have not previously been described in thyroid malignancy, however, there are some studies describing their potential role as tumor suppressors in other cancers. Downregulation of miR-126 has been observed in colorectal cancer, gastric cancer, and metastatic breast cancer. 45, 55, 56 MiR-126 overexpression has been shown to result in decreased in vitro cell proliferation in non-small cell lung cancer and breast cancer cells. 57, 58 miR-126 is located at intron 6 of chromosome 9 and is speculated to target epidermal growth factor-like domain 7 (EGFL7), which is thought to play a role in angiogenesis. [59] [60] [61] [62] Downregulation of miR-7 has been demonstrated in glioblastoma, neuroblastoma, and squamous cell cancer of the tongue.
63-65 miR-7 is also located on chromosome 9 and is speculated to control epidermal growth factor receptor (EGFR) signaling in human cancers. [65] [66] [67] To our knowledge, this is the first study to demonstrate downregulation of miR-7 and miR-126 in thyroid cancer. In addition, our study is the first to focus on difficult to diagnose histologic subtypes by systematically identifying differentially expressed miRNAs and validating the result by qRT-PCR. Several studies have attempted to identify differentially expressed miRNA between the broad grouping of benign versus malignant, however, the malignant group was not inclusive of all the difficult to diagnose histological subtypes (i.e., HCC, FPTC, and FC). Papillary thyroid cancer samples were included in the malignant category along with the more difficult-to-diagnose subtypes (i.e., HCC, FPTC, and FC) as it is the most common type of thyroid cancer. More importantly, PTC samples were included in the analysis because, although the overall malignancy rate among indeterminate lesions are relatively low (5-16%), it is the most common malignant histologic diagnosis made among the indeterminate FNAB cytologic results.
12,53,68,69 Thus, we believe including this combination of histologies, as in our study, is more representative of what is seen in the clinical setting of FNAB result with indeterminate or suspicious features.
In summary, there are a number of miRNAs that are differentially expressed between benign and malignant thyroid tumors. This study demonstrated 2 (miR-7 and miR-126) statistically significantly differentially expressed miRNAs that were found on microarray analysis and validated on TaqMan qRT-PCR. The subgroup analysis confirmed that these 2 microRNAs are significantly differentially expressed between FA and FC samples. However, as the number of samples was compromised by performing the subgroup analysis, this information needs to be further validated in FNAB samples at a larger scale. The expression of these miRNAs may serve as an adjunct to other diagnostic markers, such as clinical factors, gene rearrangement status and somatic mutation testing, in order to definitively classify difficult to diagnose histologic subtypes preoperatively. Performing functional studies that use these miRNAs may also provide additional information on thyroid tumorigenesis and potentially have therapeutic implications. This study is an ongoing effort in identifying differentially expressed miRNAs in difficult to diagnose thyroid histologic subtypes and the downregulation of these miRNAs needs to be validated in additional tumor samples, particularly in FNAB samples that were preoperatively classified as inconclusive, in order to test their utility in clinical setting.
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